TuHURA Biosciences, Inc. HURA 深 沪
已收盘 05-08 16:00:00 美东时间
2.38
-0.020
-0.83%
华盛通- 最 高2.43
- 今 开2.42
- 成交量 49.05万股
- 最 低 2.28
- 昨 收 2.40
- 总市值 1.52亿
- 52周最高 4.00
- 市盈率 静 --
- 换手率 0.77%
- 52周最低 0.41
- 委 比 58.03%
- 总股本 6368.25万
- 历史最高 190225.00
- 量 比 0.67
- 振 幅 6.25%
- 历史最低 0.41
- 每 手 1
- 风险率 0.82%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 美银大幅上调西部数据、希捷科技目标价！宝洁、Baker Hughes、Flagstar Bank、斯伦贝谢等获多家大行上调目标价
今日重点评级关注：Ascendiant Capital：维持NRX Pharmaceuticals"买入"评级，目标价从48美元升至49美元；Chardan Capital：维持Intellia Therapeutics"买入"评级，目标价从27美元升至30美元
04-28 10:07
TuHURA Biosciences Enters Loan Agreement For Credit Facility Of Up To $50M For Its Pipeline, Ongoing Clinical Trials And General Corporate Expenses
The lender is an affiliate of the Company's largest stockholder, K&V Investment One LLC. Under the terms of the loan agreement, TuHURA will have the ability to draw down monthly on the facility on an as-needed basis
04-22 19:37
美股牛股 | 半导体概念股ALMU大涨超42%！获美政府超400万美元合同，加速半导体量子通信平台发展；RVMD狂飙超41%
半导体概念股ALMU大涨超42%！获美政府合同，加速半导体量子通信平台发展；RVMD狂飙超41%，胰腺癌靶向药III期试验成功，患者生存期接近翻倍>>
04-14 19:23
12 Health Care Stocks Moving In Monday's Intraday Session
Gainers Virax Biolabs Group (NASDAQ:VRAX) stock increased by 56.4% to $0.16 du...
04-14 01:05
TuHURA Biosciences Files $50M At-The-Market Common Stock Offering With H.C. Wainwright As Sales Agent
$50,000,000Common StockWe have entered into an At the Market Offering Agreement (the "Sales Agreement"), dated November 3, 2025, with H.C. Wainwright & Co., LLC (the "Sales Agent"), relating to the shares
04-09 04:35
TuHURA Biosciences Appoints Amanda Garofalo, MSHS, as Senior Vice President of Clinical Operations
Mrs. Garofalo brings over 20 years of experience in Phase I-IV drug and biologic development TAMPA, Fla., April 7, 2026 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or th...
04-07 19:45
TuHURA Biosciences Q4 EPS $(0.13) Beats $(0.14) Estimate
TuHURA Biosciences (NASDAQ:HURA) reported quarterly losses of $(0.13) per share which beat the analyst consensus estimate of $(0.14) by 3.7 percent. This is a 90.51 percent increase over losses of $(1.37) per share from
04-01 19:52
TuHURA Biosciences Regains Nasdaq Compliance
TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, today announced that on February 26,
02-27 20:30
TuHURA Biosciences Files IND With FDA DHM1 For Study Of TBS-2025, VISTA Inhibiting Antibody, For Treatment Of mutNPM1 r/r AML In Combination With Menin Inhibitor
TBS-2025 to be investigated in combination with a menin inhibitor in mutNPM1 r/r AMLTAMPA, Fla., Feb. 17, 2026 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology
02-17 20:49
美股大行评级 | 潜在涨幅213.87%！Wave Life Sciences获Canaccord Genuity升目标价至43美元，维持"买入"评级
今日重点评级关注：Canaccord Genuity：维持Wave Life Sciences Ltd."买入"评级，目标价从40美元升至43美元；花旗：维持Palantir Technologies"买入"评级，目标价从235美元升至260美元
02-04 12:15
